Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 6 | 2023 | 573 | 1.170 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2023 | 208 | 1.170 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2023 | 5 | 0.900 |
Why?
|
| Lupus Erythematosus, Discoid | 2 | 2023 | 3 | 0.820 |
Why?
|
| Lichen Planus | 2 | 2022 | 10 | 0.770 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2019 | 17 | 0.630 |
Why?
|
| Mastitis | 1 | 2023 | 5 | 0.460 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2023 | 20 | 0.450 |
Why?
|
| Dermatomyositis | 1 | 2023 | 18 | 0.450 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 29 | 0.450 |
Why?
|
| Dermatitis | 1 | 2023 | 34 | 0.440 |
Why?
|
| Exanthema | 1 | 2023 | 38 | 0.440 |
Why?
|
| Pemphigoid, Bullous | 1 | 2022 | 12 | 0.420 |
Why?
|
| Vascular Diseases | 1 | 2023 | 116 | 0.410 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2022 | 29 | 0.410 |
Why?
|
| Lymphoma, T-Cell | 1 | 2022 | 55 | 0.400 |
Why?
|
| Skin Diseases | 1 | 2023 | 172 | 0.390 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 105 | 0.390 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 248 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 192 | 0.380 |
Why?
|
| Vulvar Diseases | 1 | 2020 | 8 | 0.360 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 1091 | 0.360 |
Why?
|
| Leukemia | 1 | 2022 | 321 | 0.350 |
Why?
|
| Scalp Dermatoses | 1 | 2019 | 10 | 0.350 |
Why?
|
| Hypopigmentation | 1 | 2019 | 5 | 0.350 |
Why?
|
| Mycobacterium leprae | 1 | 2019 | 6 | 0.340 |
Why?
|
| Leprosy | 1 | 2019 | 8 | 0.340 |
Why?
|
| Chondroma | 1 | 2018 | 8 | 0.330 |
Why?
|
| Eyelid Neoplasms | 1 | 2018 | 6 | 0.330 |
Why?
|
| Palatal Neoplasms | 1 | 2018 | 3 | 0.330 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 102 | 0.330 |
Why?
|
| Pseudolymphoma | 1 | 2018 | 9 | 0.320 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 141 | 0.320 |
Why?
|
| Scleroderma, Localized | 1 | 2017 | 9 | 0.310 |
Why?
|
| Fasciitis | 1 | 2017 | 10 | 0.300 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2018 | 129 | 0.300 |
Why?
|
| Dermatofibrosarcoma | 1 | 2017 | 13 | 0.290 |
Why?
|
| Eosinophilia | 1 | 2017 | 85 | 0.290 |
Why?
|
| Mohs Surgery | 1 | 2017 | 23 | 0.290 |
Why?
|
| Deglutition Disorders | 1 | 2018 | 118 | 0.280 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 272 | 0.260 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2015 | 61 | 0.250 |
Why?
|
| Acanthosis Nigricans | 1 | 2014 | 3 | 0.250 |
Why?
|
| Keratosis, Seborrheic | 1 | 2014 | 6 | 0.250 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2014 | 16 | 0.240 |
Why?
|
| Humans | 20 | 2023 | 87949 | 0.220 |
Why?
|
| Middle Aged | 10 | 2023 | 25477 | 0.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 141 | 0.200 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2021 | 9 | 0.200 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2021 | 19 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1347 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2012 | 262 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 400 | 0.180 |
Why?
|
| Female | 11 | 2023 | 45399 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 761 | 0.150 |
Why?
|
| Skin | 2 | 2023 | 570 | 0.150 |
Why?
|
| Erythromelalgia | 1 | 2016 | 1 | 0.140 |
Why?
|
| Thrombocythemia, Essential | 1 | 2016 | 14 | 0.140 |
Why?
|
| Polycythemia Vera | 1 | 2016 | 23 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2019 | 8780 | 0.140 |
Why?
|
| Male | 9 | 2023 | 41697 | 0.140 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 1586 | 0.120 |
Why?
|
| Rituximab | 1 | 2023 | 119 | 0.110 |
Why?
|
| Blister | 1 | 2022 | 8 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2023 | 187 | 0.100 |
Why?
|
| Collagen | 1 | 2023 | 277 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 6655 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 166 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2022 | 513 | 0.090 |
Why?
|
| Neurodermatitis | 1 | 2020 | 1 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2023 | 420 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 465 | 0.090 |
Why?
|
| Micronesia | 1 | 2019 | 5 | 0.090 |
Why?
|
| Biopsy | 1 | 2023 | 1181 | 0.080 |
Why?
|
| Adolescent | 3 | 2021 | 9111 | 0.080 |
Why?
|
| Mexico | 1 | 2019 | 68 | 0.080 |
Why?
|
| Rare Diseases | 1 | 2019 | 63 | 0.080 |
Why?
|
| Adult | 4 | 2019 | 26131 | 0.080 |
Why?
|
| Merkel cell polyomavirus | 1 | 2017 | 1 | 0.070 |
Why?
|
| Sentinel Lymph Node | 1 | 2017 | 15 | 0.070 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 498 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2436 | 0.070 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 14 | 0.070 |
Why?
|
| Immunophenotyping | 1 | 2017 | 215 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 235 | 0.070 |
Why?
|
| Cell Count | 1 | 2017 | 197 | 0.070 |
Why?
|
| Infant | 1 | 2023 | 3105 | 0.070 |
Why?
|
| Young Adult | 2 | 2019 | 6151 | 0.070 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 172 | 0.070 |
Why?
|
| Pain | 1 | 2018 | 395 | 0.070 |
Why?
|
| Skin Transplantation | 1 | 2017 | 180 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2017 | 301 | 0.070 |
Why?
|
| Phenotype | 1 | 2022 | 2424 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2019 | 546 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2015 | 48 | 0.060 |
Why?
|
| Aged | 3 | 2017 | 18750 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2017 | 247 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1210 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1786 | 0.060 |
Why?
|
| Survival Rate | 1 | 2017 | 1877 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 848 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1827 | 0.050 |
Why?
|
| Skin Ulcer | 1 | 2021 | 25 | 0.050 |
Why?
|
| Lymphoma | 1 | 2012 | 264 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2017 | 2802 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2017 | 2274 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2017 | 3661 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3650 | 0.040 |
Why?
|
| Prognosis | 1 | 2017 | 3729 | 0.040 |
Why?
|
| Melanoma | 1 | 2012 | 462 | 0.040 |
Why?
|
| Time Factors | 1 | 2017 | 5284 | 0.040 |
Why?
|
| United States | 1 | 2019 | 6809 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2016 | 65 | 0.030 |
Why?
|
| Child | 1 | 2017 | 7065 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1703 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 1744 | 0.020 |
Why?
|
| Mutation | 1 | 2016 | 4078 | 0.020 |
Why?
|